Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
latanoprost + brimonidine
- Development stage
- Phase 4
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Latanoprost + brimonidine is a fixed-dose combination ophthalmic drug used to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Latanoprost is a prostaglandin F2α analog that reduces intraocular pressure by increasing the outflow of aqueous humor through the uveoscleral pathway. Brimonidine is an alpha-2 adrenergic receptor agonist that lowers intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow. The combination leverages complementary mechanisms to enhance efficacy in reducing intraocular pressure, which helps prevent optic nerve damage and vision loss associated with glaucoma[1][3][4][5][6][8].
02
Targets
ADRA2A (α2A)ADRA2B (α2B)ADRA2C (α2C)PTGFR (Prostaglandin F2 alpha receptor)
Beyond the preview
Go deeper on latanoprost + brimonidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on latanoprost + brimonidine.